Telithroniycin (HMR 3647) is a new ketolide antimicrobial that was developed for the treatment ofcommunityacquired respiratory tract infections. We conducted a randomized, double-blind, multicenter study to compare the clinical efficacy and safety of oral telithromycin; at 800 mg once dail yfor 5 or 10 days, with that ofamoxicillin/ clavulanic acid, at 500/125 mg three times daily for 10 days, in adults with acute maxillary sinusitis (AMS) . A total of 754 patients with AMS of less than 28 days' duration were randomized to receive either telithromycin for 5 days follow ed by pla cebo for 5 days, telithromycin fo r 10 days, or amoxicillin/clavulanic acidfor 10 days. Clinical out com e was assessed at a test-of-cure (TOC) visit between days 17 and 24 and at a late post-therapy visit between days 31 and 45. Analysis ofclinical outcome on a per-protocol basis (n =434) demonstrated therapeutic equivalence among the three regimens at the TOC visit; in each treatment group , the clini cal cure rate was approximately 75%. Only a few patients (3 to 5 in each group) had relapsed by the late post-therapy follow-up visit. Telith romycin was generally saf e and well tolerated. The most common adverse events were mild or moderate gastrointestinal effects, which occurred with similarfrequency in all three group s. We conclude that 5 or 10 days of telithromycin at 800 mg once daily is as effective clinically and as well tolerated as 10 days of
Introduction
Sinusitis is one of the most prevalent diseases encountered in general practice. I Estimated to affect more than 30 million people annually in the United States. ' sinusitis is responsible for approximately 16 million physician office visits per year .' Its actual prevalence is probably higher because its major symptoms-facial pain, purulent nasal discharge, headache, and fever-are difficult to distinguish from those of the common cold or allergies , for which patients often do not consult a physician.
In patients with bacterial sinusitis, Streptococcus pneumoniae and Hemophilus influen zae account for approximately 70% of bacterial isolates.' Less frequently implicated pathogens include Moraxella catarrhalis, Streptococcus pyogenes, and staphylococci, which are often found in cases of chronic or recurrent sinusitis ." Early treatment with an antimicrobial is warranted to reduce the duration and severity of symptoms, eradicate causative pathogens, and prevent the development of permanent mucosal damage, chronic sinusitis, and rarer complications, such as optic neuritis, subdural abscess, and meningitis."
Antral sinus puncture with culture remains the gold standard for the diagnosis of acute bacterial sinusitis, but this procedure is rarely performed in general practice. Instead, antibacterial therapy is usually initiated empirically with an agent that is active against likely pathogens. However, a major concern with empiric treatment is an increase in antibacterial resistance among key pathogens. For example, penicillin resistance occurs in more than 40% of S pneumoniae strains in many regions ; many of these strains are also resistant to macrolide antibiotic s." Could your practice benefit ' from a dedicated (:T Scanner? LUTERMAN, TEL LIER, LASKO, LERO Y Patients and methods This randomized, double-blind, three-arm, parallel-group, multicenter trial was conducted between July 17, 1998, and June 16, 1999 , at 69 centers in the United States (51 centers), Canada (11), South Africa (3), Argentina (2) , and Chile (2) . The study was conducted in accordance with good clinical practice and ethical principles as set forth in the latest revisions to the Declaration of Helsinki ; the clinica l protocol was approved by an independent ethics committee or institutional review board in each country. All patients provided written informed consent prior to the initiation of study-related procedures.
'Inclusion and exclusion criteria. Patients aged 18 years or older with presumed AMS (i.e., purulent nasal discharge visualized in the middle meatus or postnasal discharge; maxillary tenderness; toothache or pain on percussion; facial pain, pressure, or tightness; or nasal congestion that responded poorly to nasal decongestants) were screened for enrollment. To be eligible for the study, patients had to have exhibited clinical symptoms of AMS (that did not require immediate surgery) for fewer than 28 days and evidence of infection on maxillary sinus x-ray Therefore, selecting an agent that retains activity against resistant strains is important in treating sinusitis.
The usual duration of oral antibacterial therapy is 10 days, and efforts have been made to develop shorterduration antibacterial regimens that have the potential to improve patient compliance, thus minimizing the risk of treatment failure and possibly decreasing resistance. 8 The effectiveness of a shorter treatment regimen depends on the intrinsic properties of the antibacterial-primarily its potency, elimination half-life, and tissue diffu sion.
Telithromycin (HMR 3647), a ketolide , has a targeted spectrum of activity that covers the common pathogens seen in acute bacterial sinu sitis-specifically, betalactamase-producing H influenzae and M catarrhalis and penicillin G-and erythromycin A-re si stant S pneumoniae.' :" The pharmacokinetic profile of oral telithromycin supports a convenient 800-mg once-daily regimen. At this dosage, telithromycin is rapidly absorbed and has a long terminal-phase elimination half-life (-10 hr). When used against common respiratory pathogens , it has a high "area under the plasma concentrationtime curve" to minimum inhibitory concentration ratio (AUC:MIC ratio).14Moreover, telithromycin concentrates in white blood cells, which suggests that it has longlasting antibacterial activ ity in tissues and penetrates into otorhinolaryngologic tissue ." All these characteristics make telithromycin an attractive option for the short-term treatment of acute maxill ary sinusitis (AMS) .
In this article, we describe our comparison of the efficacy and safety of 5-and IC-day courses of telithromycin with that of a standard lO-day regimen of amoxicillin/clavulanic acid in the treatment of AMS .
We also ca~include 9:lify laser camera, enabling immediate image evaluations. Improve the clinic;il,peHormanceofthe practice, (pre sence of an air-fluid level and/or total sinus opacity and/or~6 mm of mucosal thickening) within 48 hours of study incl usion . Exclusion criter ia included a history of chronic or recurrent sinusitis or the presence of sphenoid sinusitis , nosocomi ally acquire d sinusitis, obstruc tive anatomic lesions in the nasopharynx, suspected nonbacterial infection, docu mented resistant pathoge ns, immotile cilia syn-.drome, cystic fibros is, or odontogenic infection. Patients were excluded ifthey had taken an antibacterial within the previous 7 days. Also excluded were immunocompromised patients, patients who had a known hyper sen siti vity to a macrolide or beta-Ia ctam antibiotic, and patient s who were takin g a corticosteroid or any drug that could interfere with the effic acy and safety assess ments of the study medic ation s. Further exclusio n criteria included progressively fatal illnes s, long Q-T syndrome, seve re hypokalemia, a histor y of drug or alcohol abuse, renal or hepatic impairm ent, and lactation or pregnancy.
Study procedures and medications. Patients attended their respective study cli nics on five separate occas ions. On the first visit (day I), patient s underwent eva luation of AMS -related signs and symptoms, sinus x-rays from three separate views , a physical exa mination (including vital sig ns), 12-lead elec trocardiog raphy (ECG), and collection of blood and urine for routine laboratory safety testing. At selected study sites, sinus puncture and aspiration of sinus fluid were undertaken in some patient s who had a confirmed diagnosis of AMS; subsequent in vitro culture and antibacterial susce ptibility testing were performed at a local accredited laboratory. All isolates were submitted to a central laboratory (Clinica l Microbiology Institute; Wilsonville, Ore.) for confirmatory susceptibility testin g by disk diffusion and MIC determinations.
Patient s were randomized ( I : I: I) to one of three oral treatment groups: 800 mg of telithromycin once in the morning for 5 days, 800 mg of telith romycin once in the morning for 10 days, or 500/1 25 mg of amox icillin/ clavul anic acid three times daily for 10 days. The identit y of all study drugs was concealed by placing them in identi cal opaque capsules. Each dose of amox icillin/ clavulanic acid was administered as two capsules; one co ntained 250 mg ofamox icillin and 125 mg ofclav ulanic acid and the other contained 250 mg of amox icillin. To further ensure the maintenance of the doubl e-blind conditions, patients in both telithro mycin gro ups also receive d matchin g placebo capsules at midday and in the eve ning, and those who had been randomized to the 5-day group rece ived matching placebo capsules (morni ng, midd ay, and eve ning) for 5 days afte r the com pletio n of their active treatment.
Patients were re-evaluated for infection-related signs and symptoms during an on-therapy visit betw een days 3 and 5 and durin g three post-th erapy visits between days II and 13 (end-o f-therapy visit), betwe en days 17 and 24 All no ses are not alike...
So why are your nasal splints?
One shap e can 't fit all.
Our new design allows each splint to be customized for the nose your patients expe ct. (test-of-cure [TOC] visit), and between days 31 and 45 (late post-therapy visit). All patients underwent repeat sinus x-rays at the TOC visit as part of the assessment of clinical outcome; additional x-rays were performed during other clinic al visits for patients whose symptoms had worsened or who had required additional antibacterial therapy. When indicated by clinical failure, additional sinus punctures were performed to determine bacteriologic outcome. At the end-of-therapy and/or the TOC visits, patients underwent further blood and urine sampling , physical examination, measurement of vital signs, and 12-1eadECG . Compliance was assessed by counting unused capsules at the on-therapy and end-of-therapy visits.
Evaluation ofclinical and bacteriologic efficacy. The primary efficacy variable was clinical outcome at the TOC visit in the clinical per-protocol patient population (i.e., patients who met diagnostic criteria, who received at least one dose of ' study medication, and who were not major protocol violators). Determinations of clinical outcome were based on investigator assessments of signs and symptoms of AMS and the degree of radiologic changes on repeat x-ray . Cure was defined as (1) disappearance of infection; clinical improvement, or a return to the preinfection state with regard to all AMS-related signs and symptoms without a need for subsequent antibacterial therapy and (2) sinus x-ray findings that were normal, improved, or at least not worse. Patients whose signs and symptoms were unchanged or worse (with or without worsening on sinus x-ray) and who needed subsequent antibacterial therapy were classified as treatment failures.
Secondary efficacy variables included clinical outcome at the late post-therapy visit and bacteriologic outcome at the TOC and late post-therapy visits. Clinical cure at the late post-therapy visit was declared for those patients who had been clinically cured at the TOC visit and who did not subsequently develop signs and symptoms of new infection and who did not need further antibacterial therapy for AMS or related complications. Patients who were designated clinical failures at the TOC visit were carried forward to the late post-therapy assessment. Other clinical failures included patients who had relapsed between the TOC and late post-therapy visits and thus required additional antibacterial treatment.
For patients in whom a causative bacterial pathogen had been isolated at screening, bacteriologic outcome was rated as either satisfactory, unsatisfactory, or indeterminate.
• A satisfactory outcome was declared when (1) the causative pathogen was documented to be eradicated on repeat sinus sampling or (2) eradication was presumed in patients whose degree of clinical recovery obviated the need for follow-up sampling. Those patients in whom a bacterial strain other than the primary causative pathogen was isolated (colonization) were also considered to have achieved a satisfactory outcome in the absence of signs 580 and symptoms of active infection.
• Bacteriologic outcome was considered to be unsatisfactory when the causative pathogen persisted on repeat sinus sampling or was presumed to be persistent because of a need to initiate treatment with another antibacterial in the wake of clinical failure or worsening radiologic findings. Bacteriologic failure was also declared in patients who experienced superinfection or reinfection in 3 days or less after the completion of treatment in conjunction with the emergence of clinical and laboratory evidence of infection and a recurrence of the causative pathogen after it had been confirmed or presumed to be eradicated during earlier assessments.
• An indeterminate outcome was declared when circumstances did not allow for a clear classification of cure or failure. Factors that had an influence on this designation included a missed appointment, discontinuation of the study medication for reasons not related to the medication itself, or the administration of another antimicrobial for an infection other than sinusitis.
Evaluation ofsafety and tolerability. Safety was evaluated by analyzing adverse events, laboratory data, ECG recordings, and physical examination findings, including vital signs . All adverse events that emerged or worsened during the study were recorded and evaluated in terms of intensity and causality.
Statistical analysis. The primary objective of this study was to obtain evidence of the clinical equivalence, on a per-protocol basis at the TOC visit, of 5 and IO days of telithromycin therapy with IO days of amoxicillin/ clavulanic acid. In order to demonstrate equivalence, between-group comparisons were made in terms of the two-sided 95% confidence interval (CI) for the difference in cure rates; treatments were considered equivalent if the lower limit of the CI was -15% or greater and the upper limit crossed O. The limits of the two-sided 95% CI for between-group differences were based on an expected cure rate of 85%.
In order to achieve 90 % power, our study required a minimum of 120 patients per group. Based on an assumption that 70 % of all patients would be evaluable for clinical efficacy, we calculated that our population would have to include no fewer than 516 patients.
Once the study was under way, routine stability testing of the amoxiciIIin/clavulanic acid supply detected evidence that some of the samples in one batch had degraded. Therefore, the efficacy data on all patients who had received amoxiciIIin/clavulanic acid from this batch were declared invalid . As a result, 100 patients were unblinded and excluded from the study. A new population of patients was recruited and randomized to take their place , and the study resumed as planned.
Appropriate parametric and nonparametric tests were used to analyze between-group differences for continuous and categorical variables, respectively.
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Results
Of the 754 pat ients who were randomized in the study, 753 received at least one dose of study medication. A total of 146 patients were excluded from the clinical efficacy analysis because their x-ray findings were not consistent with a diagnosis of AMS and/or they had received degraded medication. The modified intent-to-treat population, then, was made up of 607 patients, aged 16 to 84 years (median: 39) , who had a confirmed diagnosis of AMS and who received at least one dose of study medication.
Overall, baseline demographics and disease characteristics were comparable in the three treatment groups , and no significa nt between-group differences were appare nt (table I). Analysis of infect ion charac teristics showed that 222 patients (36.6%) had experienced at least one 582 ep isode of AMS wit hin the previo us 12 mon ths, with most having undergone one to three courses of antibacterial therapy during that time . Their current episode of AMS was generally of moderate intensity, and in most patients the infection had been present for 7 days or longer prior to enrollment. Only 10 patients (1.6%) were feverish. As a reflection of the relatively young age of the study popu lation, only 28 patients (4.6%) had one or more general risk factor s for morbidity; the most common were diabetes mellitus and unspecified liver disease (14 and 7 patients, respec tively) . The use of concomitant medication such as ana lgesics , anti-inflammatory agents, and cough and cold preparations was simi lar and well balance d in the three groups .
At study's end, 423 patients were cli nica lly eva luable on a per-protocol basis (5-day telithromycin: n =146; 10- Chronic Idiopathic Urticaria: CLARINEX Tablets are indicated for the symptomati c reli ef of pruritus, reduction in the number of hives, and size of hives, in pati ents with chronic idiopathic urticaria 12 years of age and older. CONTRAINDICATIONS: CLARI NEX Tablets 5 mg are contrai ndicated in pati ents who are hypersen sitiveto this medicati on or to any of its ing redients, or to loratadine. PRECAUTIONS: Carcinogenesis, Mutagenesis , Impairment of Fertility: The carcinogenic potential of desloratadine was assessed using loratadine studies. In an 18-month study in mice and a 2-year study in rats, loratadine was administered in the diet at doses up to 40 mg/kg/day in mice (estimated desloratadine and desloratadine metabolite exposures we re approximately 3 times the AUC in human s at the recom mended dail y oral dose) and 25 mg/kg/day in rats (estimated desloratadine and desloratadine metab olite exposu res we re approximately 30 times the AUC in human s at the recommended dail y oral dose). Male mice give n 40 mg/kg/day loratadine had a significantly higherincidence of hepatocellulartumors (combined adenomas and carcinomas) than concurre nt controls. In rats, a significantly higherincidence of hepatocellular tumors (com bined ade nomas and carcinomas) was observed in mal es given 10 mg/kg/day and in mal es and femal es given 25 mg/kg/day. Th e estimated desloratadine and desloratadine metabolite exposures of rats given 10 mg/kg of loratadine were approximately 7 times the AU C in human s at the recomm end ed daily oral dose. Th e clinical significa nce of these findings du ring long -term use of desloratadine is not known.
In genotoxicity studies with desloratadine , there was no evidence of gen otoxic potential in a reve rse mutation assay (SalmonellaiE. coli mammali an microsome bacterial mut agenicity assay) or in two assays for chromosomal abe rrations (human periph eral blood lymphocyte clastoge nicity assay and mouse bone marrow micronucleus assay).
There was no effect on femal e fertility in rats at desloratadine doses up to 24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures we re approximately 130times theAUC in human s at the recomm ended daily oral dose). A male specific decrease in fertility, dem on strated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic testicular changes, occurred at an oral desloratadi ne dose of 12 mg/kg in rats (estimated desloratadine exposures we re approximately 45 times theAU Cin human s at the recommen ded dai ly oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3 mg/kg/day (estimated desloratadi ne and desloratadine metabolite exposures were approximately 8 times the AU Cin humans at the recommended dail y oral dose) .
Pregnancy Category C: Desloratadi ne was not teratogenic in rats at doses up to 48 mg/kg/day (estimated desloratadine and desloratadine metab olite exposu res were approximately 210 times the AUC in human s at the recommended dail y oral dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadineexposures wereapproximately 230 times theAUC in hu mans at the recom mended daily oral dose). In a separate study, an increase in preimplantation loss and a decreased number of implantations andfetuses were noted in femal e rats at 24 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approxi mately 120 times the AUC in human s at the reco mmended daily oral dose) . Reduced body weight and slow righting refl ex we re reported in pu ps at doses of 9 mg/kg/day or greater (estimated desloratadi ne and desloratadine metabolite exposures we re approximately 50 times or greater than the AUC in human s at the recomm ended daily oral dose) . Desloratadine had no effect on pu p devel opment at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were app roximately 7 times the AUC in humans at the recomm en ded daily oral dose) . Th ere are, however, no adeq uate and well-controlled studies in pregnant women. Because an imal reproduction studies arenot always predictive of hu man response, desloratadine should be used during preg nancy only if clearly needed.
Nursing Mothers: Desloratadine passes into breast milk, therefore a decision should be madewhetherto discont inuenursin g or to discontinuedesloratadine , taking into account the importance of the drug to the mothe r.
Pediatric Use: Th e safety and effective ness of CLARINEX Tablets in pediatric pati ents under 12 years of age have not been establis hed.
Geriatric Use : Clinical stud ies of desloratad ine did not include sufficient num bers of su bleets aged 65andover to determinewhether they respon d differently from younge r subjects. Other reported clinical experience has not identified differences between the elde rly and younger patients. In general, dose selection for an elderly pati ent should be cautious, reflectin g the greater frequ ency of decreased hepatic, renal, or cardiac function, andof concomitant disease or other drug therapy. (see CLINICAL PHARMACOLOGY -Special Populations).
Information for Patients:
Patients should be instructed to use CLARIN EX Tablets as directed . As thereare no food effects on bioavailability, patients can be instructed that CLARIN EX Tablets may be taken without regard to meals. Patients should be advised not to increase the dose or dosing freq uency as studies have not demonstrated increased effective ness at higher doses and somnolence may occur. ADVERSE REACTIONS: Allergic Rhinitis: In multi ple-dose placebo-controlled trial s, 2,834 patients rece ived CLARIN EX Tablets at doses of 2.5 mg to 20 mg daily, of whom 1,655 pati ents rece ived the recomm ended daily dose of 5 mg. In pati ents receivi ng 5 mg daily, the rate of adverse events was similar between CLARINEX and placebo-treated patients. Th e percentof patients who withd rew prematurel y due to adverse events was 2.4% in the CLARIN EX group and2.6% in the placebo grou p. Therewe re no se riousadverse events in thesetrial s in pati ent s rece iving desloratadine.All adverse events that were re ported by greater than or equal to 2% of pati ents who recei ved the reco mmen ded dail y dose of CLARINEX Tabl ets (5.0 mg once-daily), and that were more common with CLARINEX Tabletthan placebo , are listed in Table 5 .
Tahle 5
Incidence 2.1% 1.6% Th efreq uency and magn itudeof lab oratory and electrocardiog raphicabnormal ities were similar in CLARINEX and placebo-treated patients.
Th ere we re no differences in adverse events for subg roups of patients as defined by ge nde r, age, or race. Chronic Idiopathic Urticaria: In multiple-dose, place bo-controlled trials of chronicidiopathic urticari a, 211 pati ents recei ved CLARINEX Tablets and205 recei ved pl acebo. Adverse events that we re reported by greater than or equal to 2% of patients who received CLARINEX Tablets and that were more common with CLARI NEX than placebo we re (rates for CLARINEX and placeb o, respectively): headache (14%, 13%), nau sea (5%, 2%), fati gue (5%, 1%), dizziness (4%, 3%), pharyngitis (3% , 2%) , dyspepsia (3%, 1%), and myalgia (3%, 1%).
Th e following spo ntaneo us adverse events have been repo rte d du ring the marketi ng of desloratadine: tachycardia, and rarel y hypersen sitivity reactions (such as ras h, pruritus, urticaria, edema, dyspnea, and anaphylaxis), andelevated live r enzymes including bilirubin.
DRUG ABUSE AND DEPENDENCE:
There is no information to indicate that abuse or depend ency occu rs with CLARINEX Tablets. OVERDOSAGE: Informati on regarding acute overdosage is limited to expe rience from clinical trials conducted during the developme nt of the CLARINEX product. In a dose ranging trial, at doses of 10 mg and 20 mg/day som nolence was repo rted.
Sing le daily doses of 45 mg were given to normal mal e and femal e volunteers for 10 days. All ECG s obtained in this study were manuall y read in a blinded fas hion bya cardiologist. In CLARI NEX-treated subjects,therewas an increase in mean heartrate of 9.2bpm rel ati veto placebo. Th e aTinterval was corrected for heartrate (Ole) byboth theBazettand Frideri cia meth od s. Using the OT c (Bazett) there was a mean increase of 8.1 msec in CLARINEX-treated subjects relativeto placebo. Using OT c (Fridericia) there was a mean increase of 0.4 msec in CLAR INEX-treated subjects relative to placebo. No clinically rel evantadverse events were reported.
In the event of overdose, consider standard measures to remove any unabsorbed drug . Symptomatic and suppo rtive treatment is recom me nded. Desloratadineand 3-hydroxydesloratadi ne are not eliminated by hemodial ysis.
Lethality occurre d in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabol ite exposu res we re approximately 120 times the AUC in human s at the recommended dai ly oral dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposures were approximately 290 times the human daily oral dose on a mg/m 2 basis). No deaths occurred at oral doses upto 250 mg/kg in mon keys (estimated desloratad ine exposures we re approxi mately 810 times the hu man daily oral dose on a mg/m 2 basis). day telithromycin: n = 140; amoxicillin/clavulanic acid: n = 137); 184 patients were excluded from analysis because of major protocol violations {primarily an insufficient duration of treatment , an incorrect diagnosis, or missing post-treatment information). The baseline characteristics of the clinical per-protocol population, their mean active treatment durations, and the number of active doses per patient were similar among the three groups and comparable with those of the modified intent-to-treat population (data not shown). Counts of returned study medication showed that more than 90% of patients in each group took at least 70% of their doses during the study . Clinical outcome. Analysis of clinical outcome on a per-protocol basis (primary efficacy analysis) showed therapeutic equivalence between the two telithromycin regimens and the amoxicillin/clavulanic acid regimen at the TOC visit; each treatment achieved clinical cure in approximately 75% of patients (table 2) . The classification of patients with an indeterminate outcome as clinical failures in this analysis (5-day telithromycin: n = 14; 10day telithromycin: n = 14; amoxicillinlclavulanic acid: n = 20) meant that cure rates were slightly lower relative to the per-protocol analysis , from which such patients were excluded. As was the case at the TOC visit, per-protocol clinical cure rates at the late post-therapy visit were similar in the three groups-approximately 70% in each ( tween-group differences demonstrated the therapeutic equivalence of the two telithromycin regimens relative to amoxicillin/clavulanic acid therapy .
Clinical outcome according to demographic and infection characteristics. Subgroup analyses of clinical outcome at the TOC visit according to demographic and infection characteristics yielded comparable findings in the three groups, although the number of evaluable patients in some subgroups was small. Gender, age, and smoking status had no clinically relevant relationship to outcome in any group. Similar findings were observed when clinical outcome was analyzed according to current infection characteristics, including baseline x-ray findings ( Table 3 . Per-proto co l cli nical cure rat es at t he t est-of-cure visit according to in fection characteristics Telithro myci n Am oxici llin/ Su bgroup 5 days 10 days c1avulanic acid showed tha t no major respira tory pathogen (i.e. , S pneutnoniae and H infl uenzae) was res istant to study medication prio r to treat ment. Distributi on of causat ive pathogens was co mparable across the treat ment gro ups, and similar findings (in terms of the profile and distributio n of ca usa tive pathogen s) were observe d for the bacteriologically eva luab le per-protocol pop ulatio n.
Bacteriologic outcome. A satisfactory bac ter iolog ic outcome was obtained in six of seven patient s in eac h telith rom ycin gro up and in eig ht of 10 patien ts in the amox icillin/c1avulanic acid gro up at the T OC eva luation. At the late pos t-thera py eva luation, the bacteriologic outcome was satisfactory in five of seven patients in all three gro ups (per-pro toco l popul ation ). There were no cases of rec urre nce, rein fection , or superinfec tion.
Bacteriologic outcome by pathogen and resistance prof ile. Ana lysis of bacteriologic ou tcome by pathogen at
T OC in the per -protocol populatio n revealed that all isolates of S pne umoniae and H influen zae were erad icated (or presum ed to be era dica ted) followi ng both 5and IO-day therapy with telithrom ycin (table 4) . This included two S pneumoniae iso lates with reduced susce ptibility to pe nici llin G (MIC~0. 12 mg/L ), one of which also had erythromycin A resis tance , and three betalactamase-positive H influenzae isolates. All patient s infecte d with these pathogens achieve d clinical cure during tel ithrom ycin therapy, but amoxicillin/c1avulanic acid failed to era dicate two of four isolates of S pneumoniae, des pite the fac t that all isolates were susceptible to pen i- 5 84 cillin G in vitro . Both patie nts with presum ed persistence of S pneumoniae we re clinical failures. Presum ed persistence was recorded fo r one isolate of Pseudomonas aeruginosa (a path ogen outside the spectrum of telithromycin ) in the tel ithrom ycin 5-day gro up and one isolate of St reptococcus bovis in the telith rom ycin l Ovday gro up (suscep tible to telithromycin ); both patient s failed to achieve cl inica l cure.
Safety and tolerability. All patie nts who received at least one dose of study medication, except those who did not undergo a preth erapy entry assessme nt (n = 10), were included in the safe ty analysis (5-day telithromycin : n = 244; l a-day telithromycin: n = 254; amoxicillin/ c1avulanic acid: n = 24 5). Overall , 327 patients (44.0 %) experienced one or more trea tme nt-emerge nt adverse events that were consi dere d to be possibly relate d to a study medica tio n during the study (5-day telithrom ycin: n =103 [42.2%]; l Osday telithro myci n: n =119 [46.9%]; amox icillin/c1avulanic acid: n = 105 [42.9 %]) . Diarrhea and nausea were the most common adverse eve nts in eac h treatm ent gro up (table 5) . With the exceptio n of vagi nal ca ndidiasis , whic h occ urre d less fre que ntly in the 5-day telith romycin gro up than in the amoxicillin/c lav ulanic acid gro up, there wer e no significa nt differences among the three treatment gro ups in terms of the frequency of adve rse events.
A total of 41 pa tien ts (5.5 %) withdrew from the study because of adverse eve nts that were considere d to be poss ibly drug related (5-day tel ithromycin: n = 16 [6.6%];
ENT-Ear, Nose & Throat Journal ' A ug ust 2003 * Not app roved for use as a ste rilizer. ** Elect rical conn ecti ons sho uld be made only by fully qualified pro fessionals. ® UL is a registere d trademark of Underwriters Lab oratory. 10-day telithromycin: n = 14 [5.5 %]; amoxicillin/ clavulanic acid : n = 11 [4.5%]). Seven patients (1.0%) experienced at least one serious treatment-emergent adverse event during the study; adverse events in four of these patients were considered to be possibly related to the study medication by an investigator-three in the 10day telithromycin group (allergy, gastroenteritis, and pseudomembranous colitis [one patient each]) and one in the amoxicillin/clavulanic acid group (pseudomembranous colitis; the patient recovered without sequelae following treatment with metronidazole). No deaths occurred during the study . Analysis ofECG recordings showed that mean changes in the Q-Tc interval were small and within the limits of normal variability in each group, and no patient met the clinically noteworthy criterion of a Q-Tc interval of 500 or more msec . No clinically relevant between -group differences were apparent for changes in vital signs or laboratory safety data, including transaminase levels.
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Discussion
Over the past 3 decades, the susceptibility to antibiotics of many bacterial species implicated in acute bacterial sinusitis has declined dramatically . 16 This development has complicated the selection of suitable empiric antibiotic therapy for this condition. Indeed, in the United States, almost all M catarrhalis and at least 33% of H influenzae isolates produce beta-lactamase, which undermines the empiric use of beta-lactamase-susceptible drugs such as amoxicillin.'? As a result , amoxicillin/clavulanic acid and newer macrolides have gained wider acceptance in recent years as potential first-line agents for acute sinusi-586 tis. However , penicillin G resistance in the other major bacterial sinusitis pathogen, S pneumoniae, has also reached alarming levels ; because this resistance mechanism involves the alteration of penicillin-binding proteins, these isolates also show decrea sed susceptibility to amoxicillin/clavulanic acid.'? Furthermore, more than 50% of penicillin G-resistant isolates are also reported to be resistant to macro Iides, and the overall levels of macrolide resistance among S pneumoniae isolates are now thought to exceed those of penicillin resistance in many regions. v "These findings highlight the need for effective new antibacterials that have activity against the spectrum of sinusitis bacterial pathogens, including resistant strains, and that have a low potential for further selection of resistant isolates.
Our study shows that treatment with telithromycin at 800 mg once daily for 5 or 10days is as clinically effective as a lO-day course of amoxicillin/clavulanic acid for the treatment of adults with AMS. Resolution of both clinical symptoms and radiologic abnormalities (clinical cure) was achieved in approximately 75% of clinically evaluable (per-protocol) patients in each of the treatment groups at the post-therapy TOC assessment 17 to 24 days after treatment initiation. For the most part, treatment response was maintained at the late post-therapy evaluation 31 to 45 days after treatment initiation , as only a very small number of patients (3 to 5 in each group) had relapsed by the time of this assessment. The 5-day regimen of telithromycin was not associated with a higher relapse rate than was the 10-day regimen, despite a follow -up period that was longer by 5 days.
All patients included in this study had clinical signs and
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The word is out. Rabago said that the patients who used nasal irrigations "ex perienced significant improvement compared to those who did not." He said they reported fewer headaches, less congestion, less use of antibiotics and few side of effects.
"These statistically significant results are impressive and important, especially given that many patients in the study had already used all the conventional therapies for sinuS disease, without improvement," Rabago said. Sinus infections -as most who suffer from them can attest -are particularly painful and can cause headaches, runny noses, post-nasal drip, coughs and congestion. If bad enough, the infections are treated with nasal sprays that contain steroids.
But Dr. David Rabago, a clinical research fellow in the Department of Family Medicine at the UW Medical School, said his research indicates that nasal irrigation -cleansing the nasal passages with salt water -offers a simpler and drug-free treatment . symptoms and radi ologic signs of AMS , and most patients (80.2%) rated their AMS as moderate in intensity. Subgroup analyses of clinic al cure rates showed that a 5day course of telithromycin was equally effective in patients with seve re AMS and in those who had received antibiotics for the treatment of sinusitis during the previous year. Roos et al rece ntly reported clinical cure rates of 91% following a 5-or I O-day co urse of telithromycin at 800 mg once daily ." The somew hat lower clini cal cure rate s observed in our study might refle ct the fact that fewer than 10% of our patients underwent sinu s puncture , a procedure that ca n help relieve symptoms throu gh aspiration of fluid. Among our patients who did undergo sinus puncture, the clini cal outcome was cure in 85.7%, 85.7%, and 80.0% of patient s in the 5-day telithromycin , 10-day telith romy cin, and amo xicillin/cla vulani c acid group s, respective ly (per-protocol data).
We chose amox icillin/clavulanic acid as the comparator drug in this study becau se of its pro ven effic acy in the empiric treatm ent of AMS and its activity against common causative bacterial pathogen s. However, the perprotocol clinical cure rate for amoxicillin/clavulanic acid in our study (74 .5% at TOC) was lower than rates reported for this agen t in other studie s (82 to 96%).19-22Thi s can be explained to some extent by differenc es in study designs, analyses, and methodologies. For example, in many of the aforementioned studies, sinus puncture was perform ed at study entry. Moreover, the definition of clinical cure in other studies was based solely on clinical symptoms and not on radio graph ic resoluti on, which tend s to lag behind clinical findings, as we saw in our study. Finall y, in our study, clini cal cure was evaluated 7 to 14 days after the end of the 10-da y treatment course, which allowed us to identify early cases of relapse and pro vided a more rigorous measure of efficacy than that seen in many of the other amoxicillin/clav ulanic acid trial s, in which TOC was performed closer to the end of therapy.
Of all the publi shed studies of amox icillin/clav ulanic 588 acid in AMS , the findings of Camacho et al are probably closest to ours in terms of the definitions used for clinical cure and failure and the types of analy ses that were performed ." The major differ enc e between these two studies is that Camacho et al classified patients who failed treatment after receiving less than 5 days of therapy as clinic ally unevaluable. If data from our study are rean alyzed to exclude such patients from our evalu able population, clinical cure rates across all treatment groups would range fro m 77 to 79 % (instead of73 to 75 %), rate s that are comparable to the rate reported by Cam acho et al (82 %). Bacteriologic outcome was not a primary endpoint of our study, so the numb er of patients in whom sinus puncture was performed and the number of causative pathogens isolated (principally S pn eumoniae and H infl uenraei were small. All strains of S pn eum onia e (4/4) and H influ enzae (5/5) were eradicated following treatment with telithromycin, including two isolates of S pn eum onia e that exhibited reduced susceptibility to penicillin G (one of which was also resistant to erythrom ycin A) and three isolates of beta-lactamase-posit ive H influ enrae. Telithromycin ' s antibacterial activity against such strains is well documented in vitro . Bacteriolo gic efficacy was the prim ary endpoint in the study (n =336) oftelithromycin in adult AMS by Roo s et al." The y found that 91% of causative patho gens were erad icated by a 5day regimen oftelithromycin, a value comparabl e to those reported for standard durations of therapy with amoxicillinl clavul anic acid, cefdinir, and cefuroxime axetiI.2 I. 23.24 Patient compliance with oral antib acterial therap y is notoriously poor, particularly durin g the treatment of acute infection s such as AMS . 8 • 16 Because symptoms frequently subside before the patho gen is eradicated, patient s often prematurely stop taking their medi cation. The duration of treatm ent and the frequ ency of daily dosing have been sho wn to be two of the most important factors that influence compliance with an antibiotic treatment regimen. Logically, patients are more likely to be 
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TRAlVSTRACHEAL s healing time is slashed from six to eight weeks to about two weeks. Medicare covers the procedure and the one-night hospital stay.
After surgery, patients continue to see their pulmonologists, so everybod y gains with Fast Tract.
Though transtracheal oxygen therap y may be new to you, SCOOP Oxygen Therapy has a 15-year track record. It offers direct, 24-hour oxygen delivery for improved survival, reduced wor k of breathing, increased exercise
We need your surgical skills to help oxygen-dependent patients use continuous oxygen much sooner, greatly reduce healing time and free patients from the discomfort of the nasal cannula.
Fast Tract is a surgical procedure that places our SCOop® oxygen catheter in the patient's trachea . It's simple and beneficial for everyone concerned. Patients are on SCOOP oxygen delivery fastwithin 24 hours . Compared to the conventional Seldinger technique,
New Fast Tracf M procedure lets patients cut ties with primitive oxygen delivery.
For more information Circle 143 on Reader Service Card LUTERMAN , TELLIER , LAS KO , LEROY compli ant with a short-duration, once-daily treatment regimen, such as the 5-day telithromy cin regimen used in this study, than with a prolon ged regimen that requir es multiple daily doses. In addition to being associated with disease recurrence and significant healthc are expenditure, poor compliance may have broader ramifications, such as encouraging selection of resistant isolates." Compliance with medication was generally good in our study . Unfortunately, one of the drawbacks of randomized, double -dummy studies is that they do not reflect real-world conditions, and therefore reliable evaluation s of the effects that factors such as dosing freq uency and duration have on comp liance are not possi ble.
Another rationale for shorte ning treatment regimens is the potential for improved tolerability. In our study, both of the telithromycin regimens were generally well tolerated. Adverse events were mostly mild or moderate in intensity and were genera lly similar in nature and frequency to those that occurred with amoxicillin/clav ulanic acid. The most frequently reported adverse events in each of the three groups were diarrhea and nausea. Notably, a significantly lower incidence of vaginal cand idiasis occurred among women who received telithromycin for 5 days than in those who received amoxicillin/clavulanic acid, which is of clinical relev ance in view of the frequency with which this adverse effect occurs with broadspectrum antibiotics. Differences in abnormal laboratory values rated as clinically noteworthy were not statistically signific ant among the treatment group s, and there were no treatment-related change s in vital signs or clinically relevant changes in Q-Tc intervals.
In conclusio n, the results of our study demonstrate that a 5-or l O-day course of telithromycin at 800 mg once daily is as effec tive clin ically and was equally well tolerated as a lO-day treatment with amoxicillin/clav ulanic acid. Thus, short-course treatme nt with telithromycin for 5 days , with the convenience of once -daily administration, appears to be a valuable option for the treatment of acute bacterial sinusitis in adults.
